This Act prohibits the use of federal taxpayer funds for gender transition procedures and prevents federal subsidies under the Affordable Care Act from being used to cover such procedures.
Roger Marshall
Senator
KS
The End Taxpayer Funding of Gender Experimentation Act of 2025 prohibits the use of any federal money for gender transition procedures, including for federal employees and at federal facilities. This ban also extends to the Affordable Care Act (ACA) marketplace, preventing individuals from using federal premium tax credits or cost-sharing reductions to cover plans that include these procedures. The law strictly defines "gender transition procedures" while excluding treatments for certain disorders of sex development or procedures necessary to prevent imminent death.
The “End Taxpayer Funding of Gender Experimentation Act of 2025” is a direct and sweeping piece of legislation designed to cut off all federal funding streams—including trust funds and subsidies—from paying for what it defines as “gender transition procedures.” This bill is not subtle; it goes straight for the wallet, targeting individuals, federal facilities, and even the Affordable Care Act (ACA) marketplace.
The core of the bill is a strict prohibition (Section 101) against using any federal money to pay for gender transition procedures. This ban applies across the board: if you get healthcare at a federal facility, or if your coverage is funded by the government, that coverage cannot include these specific procedures. Crucially, while states and private entities can still buy separate coverage, they must use money that is entirely non-federal. This means states can’t use their share of federal matching funds (like Medicaid dollars) to help cover this care, effectively making it impossible for many low-income individuals to access it.
This bill uses very specific, and very broad, definitions. It defines Sex strictly as biological male or female based on reproductive systems. Gender Transition Procedure is defined broadly to include hormonal treatments (like puberty blockers or high-dose cross-sex hormones) and various surgeries (orchiectomy, hysterectomy, mastectomy, etc.) when done for the purpose of gender transition. It even bans the removal of “any otherwise healthy body part or tissue” if the goal is to feminize or masculinize features. If you’re a professional navigating this space, the sheer breadth of this definition means many standard treatments would be caught in this net.
There are a few exceptions, mostly for medical necessity: treatment for infections or injuries resulting from a previous procedure, care needed to prevent imminent death, and treatment for medically verifiable disorders of sex development (DSDs). For example, a minor needing puberty blockers to treat precocious puberty (a medical condition where puberty starts too early) would still be covered, but a minor seeking them for gender transition would not.
For the millions of Americans who buy insurance through the ACA marketplace, Title II is the part that will really matter. Section 201 clarifies that if a health plan includes coverage for gender transition procedures, you cannot use federal premium tax credits or cost-sharing reductions to pay for that plan. Think of it like this: if you rely on those subsidies to make your monthly premium affordable, you’d have to choose a plan that excludes this specific coverage, or pay the full, unsubsidized cost of a plan that includes it.
This also hits small business owners. If you claim the small employer health insurance tax credit (Section 45R) to help cover employee premiums, your plan will be disqualified from receiving that credit if it covers gender transition procedures. For a small employer trying to offer comprehensive benefits, this forces a difficult choice: drop the coverage or lose the tax break.
The practical effect of this bill is creating a significant access wall for transgender individuals, particularly those who rely on federal programs like Medicaid or ACA subsidies. If you are a young person or a working professional who needs hormonal care and relies on subsidized insurance, this bill forces you into an impossible situation where you must choose between affording basic coverage and accessing medically necessary, gender-affirming care. The bill essentially mandates that anyone seeking this specific care must pay for it entirely out-of-pocket, using only non-federal funds, which often means it becomes unaffordable for those not wealthy enough to self-pay.
While the stated intent is to stop taxpayer funding of these procedures, the mechanism used—disqualifying plans from subsidies—means that the burden of this policy falls squarely on the individual consumer and small businesses trying to provide comprehensive care. The changes to ACA subsidies and small employer credits are set to take effect for plan years beginning more than one year after the bill is enacted, giving the insurance market a runway to adjust to these new restrictions.